Clinical characteristics.

GATA1-related cytopenia is characterized by thrombocytopenia and/or anemia ranging from mild to severe. One or more of the following may also be present: platelet dysfunction, mild β-thalassemia, neutropenia, and congenital erythropoietic porphyria (CEP) in males. Thrombocytopenia typically presents in infancy as a bleeding disorder with easy bruising and mucosal bleeding (e.g., epistaxis). Anemia ranges from minimal (mild dyserythropoiesis) to severe (hydrops fetalis requiring in utero transfusion). At the extreme end of the clinical spectrum, severe hemorrhage and/or erythrocyte transfusion dependence are life long; at the milder end, anemia and the risk for bleeding may decrease spontaneously with age. Heterozygous females may have mild-to-moderate symptoms such as menorrhagia.

Diagnosis/testing.

Diagnostic laboratory findings usually include macrothrombocytopenia (low number of platelets that are larger than normal) and/or anemia with red cell indices that may be micro-, normo- or macrocytic. Defects in platelet aggregation in response to agonists may be seen. In some cases electron microscopy reveals reduced numbers of platelet alpha granules and dysplastic features in platelets and megakaryocytes.

Management.

Treatment of manifestations: Platelet transfusions for moderate-to-severe epistaxis, gingival bleeding, or gastrointestinal bleeding; no specific treatment for mild symptoms (easy bruisability); erythrocyte transfusions when anemia is symptomatic (fatigue, tachycardia).

Prevention of primary manifestations: For severe cases, bone marrow transplantation (BMT) can be curative.

Surveillance: Monitoring complete blood counts (with frequency depending on disease severity) to inform supportive care; monitoring those undergoing repeated erythrocyte transfusions for iron overload.

Agents/circumstances to avoid: Those with thrombocytopenia should avoid antiplatelet agents including aspirin and nonsteroidal anti-inflammatory agents (e.g., ibuprofen). Those with thrombocytopenia and/or platelet aggregation defects should avoid contact sports or activities with a high risk of trauma.

Evaluation of relatives at risk: If a GATA1 pathogenic variant has been identified in the family, complete blood counts and molecular genetic testing of at-risk relatives can be offered. At-risk relatives who choose not to have molecular genetic testing should have complete blood counts to evaluate for thrombocytopenia, anemia, or neutropenia.

Genetic counseling.

GATA1-related cytopenia is inherited in an X-linked manner. If the mother of an affected male has a GATA1 pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Affected males pass the pathogenic variant to all of their daughters and none of their sons. Testing for at-risk family members and prenatal testing for a pregnancy at increased risk are possible once the pathogenic variant has been identified in the family.

Suggestive Findings

GATA1-related cytopenia should be suspected in an individual with the following:

• Thrombocytopenia and/or anemia ranging from mild to severe (including fetal hydrops)
• One or more of the following:
  • Platelet dysfunction
  • Mild β-thalassemia
  • Neutropenia
  • Congenital erythropoietic porphyria (CEP)
• Family history consistent with X-linked inheritance
• No evidence of Wiskott-Aldrich syndrome (WAS), an X-linked disorder of microthrombocytopenia that can present with or without immunodeficiency

Note: 1) Initial testing should include complete blood count, examination of the blood smear, and bone marrow aspirate and biopsy to confirm that cytopenia results from ineffective hematopoiesis rather than peripheral destruction or sequestration. 2) Hematologic findings in GATA1-related cytopenia are variable and usually nonspecific (i.e., seen in numerous conditions and thus by themselves not indicative of a specific diagnosis). 3) Affected individuals are typically male; females will usually present with milder findings.

Establishing the Diagnosis

Male proband. The diagnosis of GATA1-related cytopenia is established in a male proband with cytopenia resulting from ineffective hematopoiesis by identification of a hemizygous pathogenic variant in GATA1 by molecular genetic testing (see Table 1).

Female proband. The diagnosis of GATA1-related cytopenia may be established in a female proband with hematopoietic cytopenias by identification of a pathogenic variant in GATA1 by molecular genetic testing (Table 1). A pattern of skewed X-inactivation would support the diagnosis. Note: This disorder is not usually first diagnosed in a family via a female proband.

Molecular testing approaches can include single-gene testing, use of a multigene panel, and more comprehensive genomic testing:

• Single-gene testing. Sequence analysis of GATA1 is performed. Although no exon or whole-gene deletions or duplications have been reported as a cause of GATA1-related cytopenias, some laboratories offer gene-targeted deletion/duplication analysis if a pathogenic variant is not found.
• A multigene panel that includes GATA1 and other genes of interest (see Differential Diagnosis) may be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
  For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
• More comprehensive genomic testing (when available) including exome sequencing and genome sequencing may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation).
  For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

Clinical Description

Individuals with GATA1-related cytopenia have thrombocytopenia and/or anemia.

Males

• Males typically present in infancy with a bleeding disorder:
  • Affected individuals have easy bruising and mucosal bleeding (e.g., epistaxis).
  • Physical examination may reveal petechiae, ecchymoses, or splenomegaly.
  • Excessive hemorrhage and/or bruising can occur either spontaneously or after trauma or surgery.
• Anemia, the other major clinical problem in males with this disorder, ranges from minimal with only mild dyserythropoiesis [Freson et al 2001] to severe hydrops fetalis requiring in utero transfusions [Nichols et al 2000].
  • Anemia can be so severe that affected males are red blood cell transfusion dependent from birth [Freson et al 2002].
  • In one family, moderately severe anemia was associated with congenital erythropoietic porphyria (CEP) with no pathogenic variants detected in UROS; an Arg216Trp pathogenic variant was identified in GATA1 [Phillips et al 2007]. The affected individual also had bullous skin lesions associated with porphyria. In two additional probands with CEP, anemia and thrombocytopenia, a pathogenic variant in UROS or SEC23B was detected in addition to an Arg216Trp variant in GATA1 [Di Pierro et al 2015].
  • Variable mild-to-moderate neutropenia with macrocytic anemia and normal platelet counts has been reported in association with a germline pathogenic variant resulting in a truncated protein (GATA-1s; discussed in Molecular Genetics, Pathogenic variants) [Hollanda et al 2006, Sankaran et al 2012, Zucker et al 2016]; family members with severe neutropenia were predisposed to infection [Hollanda et al 2006].
• Splenomegaly is commonly present in one form of GATA1-related disease (see Genotype-Phenotype Correlations). Typically, no other physical anomalies are present.

Laboratory findings in males

• Complete blood count showing the following:
  • Platelet counts are usually low (10-100 x 10³/µL), but vary considerably with specific pathogenic variants. Normal counts have also been reported (150-400 x 10³/µL), including individuals with a germline pathogenic variant resulting in a truncated protein (GATA-1s; see Molecular Genetics, Pathogenic variants) causing congenital anemia [Hollanda et al 2006, Sankaran et al 2012]. The platelets are typically larger than normal (macrothrombocytopenia).
  • Anemia (hematocrit 16%-35%; normal: 35%-45%) may be present; the severity varies with the specific pathogenic variant. Red cell indices are normochromic but may be mildly microcytic (75-79 fL) or macrocytic (101-103 fL) (normal: 80-99 fL).
  • Significant persistent neutropenia (0.5-2.8 x 10³/µL; normal 1.9-8.0 x 10³/µL) was observed in one family with a specific GATA1 pathogenic variant [Hollanda et al 2006]; findings were variable in families with other GATA1 variants [Sankaran et al 2012, Zucker et al 2016].
  Note: Thrombocytopenia, anemia, and neutropenia are usually defined as two standard deviations below values observed in the normal population.
• Peripheral blood smear that may show the following:
  • Some platelets that are larger and more spherical than the typical discoid morphology. Platelets may be pale, reflecting reduced granularity.
  • Variation in erythrocyte size and shape and hypochromia, reflecting low hemoglobin content
  • Decreased neutrophils with abnormal morphology; this rare finding was reported in one family with an unusual germline pathogenic variant resulting in a truncated protein (GATA-1s; discussed in Molecular Genetics, Pathogenic variants) [Hollanda et al 2006].
• Bone marrow biopsy that may show the following:
  • Hyper- or hypocellularity
  • Increased or decreased numbers of megakaryocytes
  • Small, dysplastic megakaryocytes with signs of incomplete maturation
  • Dyserythropoiesis
  • Hypocellularity of erythroid and granulocytic lineages
  • Mild-to-moderate reticulin fibrosis [Åström et al 2015]
• Platelet function abnormalities. Defects in platelet aggregation in response to agonists (e.g., ristocetin, adenosine diphosphate, epinephrine, or collagen) occur in some cases [Thompson et al 1977, Freson et al 2001, Balduini et al 2004, Hollanda et al 2006]. These studies can be normal in some affected individuals.
• Electron microscopy. Findings in some cases include reduced numbers of platelet alpha granules and dysplastic features in megakaryocytes and platelets.
• In subtypes associated with globin chain imbalance, findings consistent with mild hemolysis, including mild reticulocytosis, elevated LDH, and low haptoglobin, may be present. In addition, HbA2 and HbF may be elevated.

Findings in heterozygous females. Females may manifest platelet abnormalities [White 2007] and mild-to-moderate symptoms such as menorrhagia or easy bruising, presumably related to the proportion of relevant cells that contain the pathogenic GATA1 variant on the active X chromosome [Nichols et al 2000; Raskind et al 2000; Balduini et al 2004; Del Vecchio et al 2005; Raskind, unpublished observations].

• Platelet counts may be normal or mildly to moderately decreased [Nichols et al 2000]; this may depend on the nature of the pathogenic variant or other (either genetic or environmental) modifiers.
• Morphologic abnormalities of platelets can be detected by electron microscopy [White 2007] and in some instances on peripheral blood smears [Tubman et al 2007].
• Two distinct platelet morphologies can be observed on peripheral blood smear, reflecting mosaicism secondary to random X-chromosome inactivation.

Course and prognosis. The long-term course in both males and females depends on disease severity:

• At the extreme end of the clinical spectrum, severe hemorrhage and/or erythrocyte transfusion dependence are life long.
• At the milder end, the risk for bleeding may spontaneously decrease with age, despite continued thrombocytopenia [Mehaffey et al 2001, Del Vecchio et al 2005].
• Some affected individuals may be recognized only after incidental findings of mild-to-moderate cytopenias on blood count analysis. These individuals have a good prognosis.

Genotype-Phenotype Correlations

Table 2 outlines the relationship between specific GATA1 pathogenic variants and associated phenotypic features.

For further information on murine and in vitro experiments involving GATA-1, see Molecular Genetics, Pathogenic variants.

Nomenclature

Until pathogenic variants in GATA1 were shown to underlie this heterogeneous disorder, a variety of terms were coined for the different clinical presentations. The first term used was X-linked thrombocytopenia with thalassemia (XLTT) [Raskind et al 2000]. Other terms used in the past and still in the current literature are "familial dyserythropoietic anemia and thrombocytopenia" [Nichols et al 2000, Del Vecchio et al 2005] and "X-linked macrothrombocytopenia" [Freson et al 2001].

To describe individuals with a clinical diagnosis of Diamond-Blackfan anemia in whom GATA1 pathogenic variants are identified and ribosomal protein variants are absent, the authors suggest the phrase "variant DBA associated with pathogenic variant of GATA1."

Prevalence

GATA1-related cytopenia is rare; the prevalence is not known. To date, hematopoietic disease caused by inherited pathogenic variants in GATA1 has been reported in 22 families [Nichols et al 2000, Freson et al 2001, Mehaffey et al 2001, Freson et al 2002, Yu et al 2002, Balduini et al 2004, Del Vecchio et al 2005, Hughan et al 2005, Phillips et al 2005, Hollanda et al 2006, Sankaran et al 2012, Singleton et al 2013, Hermans et al 2014, Klar et al 2014, Parrella et al 2014, Åström et al 2015, Di Pierro et al 2015, Zucker et al 2016].

GATA1 pathogenic variants may be more common than previously appreciated, particularly in persons with mild, unexplained thrombocytopenia/"gray platelet syndrome" present since birth [Tubman et al 2007] or individuals with congenital hypoplastic anemia/Diamond-Blackfan anemia with no ribosomal protein pathogenic variants [Sankaran et al 2012].

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with GATA1-related cytopenia, the following are recommended:

• Complete blood count and examination of the peripheral smear to assess the degree of cytopenia(s)
• Detailed history of age at which hematologic disease was manifest
• Documentation of abnormal/unexpected bleeding episodes and platelet counts obtained at the time of the episodes to help determine whether platelet function is abnormal and whether disease severity has changed over time
  Note: Platelet aggregation studies may also be useful to identify functional abnormalities that predict a greater risk of bleeding for any given platelet count, but studies can be difficult to interpret when platelet counts are lower than 100,000/μL.
• Consultation with a clinical geneticist and/or genetic counselor

Treatment of Manifestations

Individuals with GATA1-related cytopenia are treated supportively.

Thrombocytopenia. Individuals with moderate-to-severe epistaxis, gingival bleeding, or gastrointestinal bleeding should receive platelet transfusions. Transfusion requirements vary from person to person as bleeding can be related to quantitative and/or qualitative platelet defects.

• For individuals with thrombocytopenia and/or platelet aggregation defects, DDAVP treatment may be helpful for short-term management of mild-to-moderate bleeding.
• Individuals who are only mildly symptomatic (easy bruisability without mucosal or more severe bleeding) do not require specific treatment.
• There is no evidence that splenectomy is beneficial in people with GATA1-related disease, although this treatment may be considered if splenomegaly is severe. Although splenectomy may improve the cytopenias, platelet dysfunction will not be improved.

Anemia. Erythrocyte transfusions are indicated when anemia is symptomatic (fatigue, tachycardia).

• Iron overload and the development of alloantibodies may limit chronic transfusion therapy.
• Extended pre-transfusion red blood cell phenotyping and matching for minor erythrocyte antigens in individuals receiving frequent transfusions can reduce the risk of alloimmunization.

Neutropenia. Individuals with neutropenia who present with fever should be evaluated promptly with a physical examination, complete blood count, and blood culture and should receive appropriate parenteral antibiotics.

Bone marrow transplantation (BMT). For severe cases, BMT can be curative [Hollanda et al 2006, Phillips et al 2007, Parrella et al 2014].

• BMT should be considered in individuals with severe phenotypes of GATA1-related cytopenia, particularly if an HLA-matched donor is available.
• While BMT may offer a cure, clinical experience with BMT in this disease is limited and families must be counseled on the significant risks and morbidity associated with BMT.

Prevention of Primary Manifestations

The only definitive cure for GATA1-related cytopenia is bone marrow transplantation.

Prevention of Secondary Complications

Individuals with thrombocytopenia and/or platelet aggregation defects should receive a platelet transfusion prior to surgical or invasive dental procedures.

Individuals with neutropenia should be counseled regarding their increased risk of infection. They should avoid crowds and contact with individuals who have communicable diseases. When febrile, those who are severely neutropenic (absolute neutrophil count <500/µL) should seek medical attention; typically blood cultures are obtained and parenteral antibiotics are administered to avoid the possibility of life-threatening sepsis.

Surveillance

Depending on the phenotype of the disease, complete blood counts should be monitored so that supportive care can be provided as needed. Individuals with mild cytopenias require infrequent monitoring (yearly), while those with severe cytopenias who require transfusions should have complete blood counts monthly or as indicated by clinical signs and symptoms.

Individuals undergoing repeated erythrocyte transfusions should be monitored for iron overload and managed appropriately with iron chelation therapy.

Agents/Circumstances to Avoid

Individuals with thrombocytopenia should avoid antiplatelet agents including aspirin and nonsteroidal anti-inflammatory agents (e.g., ibuprofen).

Individuals with thrombocytopenia and/or platelet aggregation defects should be advised to avoid contact sports or activities with a high risk of trauma.

Individuals with significant neutropenia should avoid crowds and close contact with persons who have a communicable disease to minimize risk of infection.

Individuals with significant splenomegaly should avoid contact sports, which involve increased risk for traumatic splenic rupture.

Evaluation of Relatives at Risk

It is appropriate to evaluate apparently asymptomatic at-risk relatives of an affected individual in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.

Evaluations can include:

• Molecular genetic testing for the familial GATA1 pathogenic variant;
• A screening complete blood count to evaluate for thrombocytopenia, anemia, or neutropenia.
  Note: Platelet, erythrocyte, and neutrophil counts can vary significantly in individuals with GATA1 pathogenic variants; normal results do not rule out the possibility that the relative has a GATA1 pathogenic variant.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

Other

Unlike immune-mediated platelet disorders such as immune thrombocytopenic purpura, GATA1-related thrombocytopenia does not respond to steroid or immunoglobulin therapy.

Supplemental erythropoietin therapy is unlikely to be effective because the anemia is secondary to ineffective erythropoiesis, not erythropoietin deficiency.

Mode of Inheritance

GATA1-related cytopenia is inherited in an X-linked manner.

Risk to Family Members

Parents of a male proband

• The father of an affected male will not have the disorder nor will he be hemizygous for the GATA1 pathogenic variant; therefore, he does not require further evaluation/testing.
• In a family with more than one affected individual, the mother of an affected male is an obligate heterozygote (carrier). If a woman has more than one affected son and no other affected relatives and if the pathogenic variant cannot be detected in her leukocyte DNA, she has germline mosaicism (evidence of germline mosaicism has not been observed).
• If a male is the only affected family member (i.e., a simplex case), the mother may be a heterozygote (carrier) or the affected male may have a de novo GATA1 pathogenic variant, in which case the mother is not a carrier. Because very few families with GATA1 pathogenic variants have been described to date, the frequency of de novo pathogenic variants is not known.

Sibs of a male proband. The risk to sibs depends on the genetic status of the mother:

• If the mother of the proband has a GATA1 pathogenic variant, the chance of transmitting it in each pregnancy is 50%.
  • Males who inherit the pathogenic variant will be affected.
  • Females who inherit the pathogenic variant will be heterozygous and will usually not be affected, but may have reduced hematocrits and platelet counts to a variable degree. Large platelets may also be present and those with the globin chain imbalance subtype may have splenomegaly and slightly decreased β-globin synthesis.
• If the proband represents a simplex case (i.e., a single occurrence in a family) and if the GATA1 pathogenic variant cannot be detected in the leukocyte DNA of the mother, the risk to sibs is slightly greater than that of the general population (though still <1%) because of the theoretic possibility of maternal germline mosaicism.

Offspring of a proband. Affected males transmit the GATA1 pathogenic variant to:

• All of their daughters, who will be carriers (heterozygotes) and will usually not be affected (see Clinical Description);
• None of their sons.

Other family members. The proband's maternal aunts may be at risk of being heterozygotes (carriers) for the pathogenic variant and the aunts' offspring, depending on their sex, may be at risk of being heterozygotes (carriers) for the pathogenic variant or of being affected.

Heterozygote Detection

Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the pathogenic variant has been identified in the proband.

Note: Females who are heterozygotes (carriers) for this X-linked disorder may develop clinical findings related to the disorder (see Clinical Description).

Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

Family planning

• The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.

Prenatal Testing and Preimplantation Genetic Testing

Once the GATA1 pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for GATA1-related cytopenia are possible.

Cancer and Benign Tumors

Two hematopoietic disorders in children with Down syndrome (DS) associated with acquired (somatic) pathogenic variants in exon 2 of GATA1 are transient myeloproliferative disorder (TMD) and acute megakaryoblastic leukemia (M7 subtype, DS-AMKL) [Wechsler et al 2002, Elagib et al 2003, Waltzer et al 2003, Ahmed et al 2004, Creutzig et al 2005, Crispino 2005a, Crispino 2005b, Muntean et al 2006, Roy et al 2009, Roberts et al 2013].

TMD, found in up to 10% of infants with DS, usually resolves spontaneously; however, TMD confers a markedly increased risk for DS-AMKL [Wechsler et al 2002, Ahmed et al 2004, Crispino 2005a, Crispino 2005b, Hitzler & Zipursky 2005]. The acquired exon 2 variants lead to premature arrest of translation and reinitiation of protein synthesis at the downstream methionine codon at position 83, and result in the production of GATA-1 short isoform (GATA-1s) that lacks the amino-terminal activation domain. Some splice site variants also result in generation of GATA-1s. Two novel GATA1 variants involving internal deletions of either amino acids 77-199 or 74-88 were identified in six individuals with TMD [Toki et al 2013]. How GATA1 variants synergize with trisomy 21 to promote DS-AMKL is unknown.

One individual with severe anemia and thrombocytopenia caused by a pathogenic missense variant in GATA1 (p.Val205Met) developed myelodysplastic syndrome 18 years after a failed bone marrow transplantation. It is not clear whether the MDS with a clonal deletion of 20q was due to the underlying disease caused by the pathogenic variant of GATA1, bone marrow transplant associated toxicity, or both [Authors, unpublished data].

Literature Cited

• Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O'Marcaigh A, Wynn R, Stevens R, Addison M, King D, Stewart B, Gibson B, Roberts I, Vyas P. Natural history of GATA1 mutations in Down syndrome. Blood. 2004;103:2480–9. [PubMed: 14656875]
• Åström M, Hahn-Strömberg V, Zetterberg E, Vedin I, Merup M, Palmblad J. X-linked thrombocytopenia with thalassemia displays bone marrow reticulin fibrosis and enhanced angiogenesis: comparisons with primary myelofibrosis. Am J Hematol. 2015;90:E44–8. [PubMed: 25421114]
• Balduini CL, Pecci A, Loffredo G, Izzo P, Noris P, Grosso M, Bergamaschi G, Rosti V, Magrini U, Ceresa IF, Conti V, Poggi V, Savoia A. Effects of the R216Q mutation of GATA-1 on erythropoiesis and megakaryocytopoiesis. Thromb Haemost. 2004;91:129–40. [PubMed: 14691578]
• Balduini CL, Savoia A. Inherited thrombocytopenias: molecular mechanisms. Semin Thromb Hemost. 2004;30:513–23. [PubMed: 15497094]
• Campagna DR, de Bie CI, Schmitz-Abe K, Sweeney M, Sendamarai AK, Schmidt PJ, Heeney MM, Yntema HG, Kannengiesser C, Grandchamp B, Niemeyer CM, Knoers NV, Swart S, Marron G, van Wijk R, Raymakers RA, May A, Markianos K, Bottomley SS, Swinkels DW, Fleming MD. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations. Am J Hematol. 2014;89:315–9. [PMC free article: PMC3943703] [PubMed: 24166784]
• Campbell AE, Wilkinson-White L, Mackay JP, Matthews JM, Blobel GA. Analysis of disease-causing GATA1 mutations in murine gene complementation systems. Blood. 2013;121:5218–27. [PMC free article: PMC3695365] [PubMed: 23704091]
• Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia. 2005;19:1355–60. [PubMed: 15920490]
• Crispino JD. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol. 2005a;16:137–47. [PubMed: 15659348]
• Crispino JD. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatr Blood Cancer. 2005b;44:40–4. [PubMed: 15390312]
• Del Vecchio GC, Giordani L, De Santis A, De Mattia D. Dyserythropoietic anemia and thrombocytopenia due to a novel mutation in GATA-1. Acta Haematol. 2005;114:113–6. [PubMed: 16103636]
• Di Pierro E, Russo R, Karakas Z, Brancaleoni V, Gambale A, Kurt I, Winter SS, Granata F, Czuchlewski DR, Langella C, Iolascon A, Cappellini MD. Congenital erythropoietic porphyria linked to GATA1-R216W mutation: challenges for diagnosis. Eur J Haematol. 2015;94:491–7. [PubMed: 25251786]
• Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood. 2004;103:390–8. [PubMed: 14504084]
• Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 2003;101:4333–41. [PubMed: 12576332]
• Ferreira R, Ohneda K, Yamamoto M, Philipsen S. GATA1 function, a paradigm for transcription factors in hematopoiesis. Mol Cell Biol. 2005;25:1215–27. [PMC free article: PMC548021] [PubMed: 15684376]
• Fox AH, Liew C, Holmes M, Kowalski K, Mackay J, Crossley M. Transcriptional cofactors of the FOG family interact with GATA proteins by means of multiple zinc fingers. EMBO J. 1999;18:2812–22. [PMC free article: PMC1171362] [PubMed: 10329627]
• Freson K, Devriendt K, Matthijs G, Van Hoof A, De Vos R, Thys C, Minner K, Hoylaerts MF, Vermylen J, Van Geet C. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood. 2001;98:85–92. [PubMed: 11418466]
• Freson K, Matthijs G, Thys C, Marien P, Hoylaerts MF, Vermylen J, Van Geet C. Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. Hum Mol Genet. 2002;11:147–52. [PubMed: 11809723]
• Ged C, Moreau-Gaudry F, Richard E, Robert-Richard E, de Verneuil H. Congenital erythropoietic porphyria: mutation update and correlations between genotype and phenotype. Cell Mol Biol (Noisy-le-grand). 2009;55:53–60. [PubMed: 19268002]
• Hermans C, De Waele L, Van Geet C, Freson K. Novel GATA1 mutation in residue D218 leads to macrothrombocytopenia and clinical bleeding problems. Platelets. 2014;25:305–7. [PubMed: 23971719]
• Hindmarsh JT. The porphyrias: recent advances. Clin Chem. 1986;32:1255–63. [PubMed: 3521939]
• Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005;5:11–20. [PubMed: 15630411]
• Hollanda LM, Lima CS, Cunha AF, Albuquerque DM, Vassallo J, Ozelo MC, Joazeiro PP, Saad ST, Costa FF. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet. 2006;38:807–12. [PubMed: 16783379]
• Hughan SC, Senis Y, Best D, Thomas A, Frampton J, Vyas P, Watson SP. Selective impairment of platelet activation to collagen in the absence of GATA1. Blood. 2005;105:4369–76. [PubMed: 15701726]
• Kaneko K, Furuyama K, Fujiwara T, Kobayashi R, Ishida H, Harigae H, Shibahara S. Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia. Haematologica. 2014;99:252–61. [PMC free article: PMC3912954] [PubMed: 23935018]
• Klar J, Khalfallah A, Arzoo PS, Gazda HT, Dahl N. Recurrent GATA1 mutations in Diamond-Blackfan anaemia. Br J Haematol. 2014;166:949–51. [PubMed: 24766296]
• Kratz CP, Niemeyer CM, Karow A, Volz-Fleckenstein M, Schmitt-Gräff A, Strahm B. Congenital transfusion-dependent anemia and thrombocytopenia with myelodysplasia due to a recurrent GATA1(G208R) germline mutation. Leukemia. 2008;22:432–4. [PubMed: 17713552]
• Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37:613–9. [PubMed: 15895080]
• Lindeboom F, Gillemans N, Karis A, Jaegle M, Meijer D, Grosveld F, Philipsen S. A tissue-specific knockout reveals that Gata1 is not essential for Sertoli cell function in the mouse. Nucleic Acids Research. 2003;31:5405–12. [PMC free article: PMC203309] [PubMed: 12954777]
• Lowry JA, Mackay JP. GATA-1: one protein, many partners. Int J Biochem Cell Biol. 2006;38:6–11. [PubMed: 16095949]
• Mehaffey MG, Newton AL, Gandhi MJ, Crossley M, Drachman JG. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood. 2001;98:2681–8. [PubMed: 11675338]
• Muntean AG, Ge Y, Taub JW, Crispino JD. Transcription factor GATA-1 and Down syndrome leukemogenesis. Leuk Lymphoma. 2006;47:986–97. [PubMed: 16840187]
• Nichols KE, Crispino JD, Poncz M, White JG, Orkin SH, Maris JM, Weiss MJ. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet. 2000;24:266–70. [PubMed: 10700180]
• Noris P, Pecci A, Di Bari F, Di Stazio MT, Di Pumpo M, Ceresa IF, Arezzi N, Ambaglio C, Savoia A, Balduini CL. Application of a diagnostic algorithm for inherited thrombocytopenias to 46 consecutive patients. Haematologica. 2004;89:1219–25. [PubMed: 15477207]
• Nurden AT, Nurden P. The gray platelet syndrome: Clinical spectrum of the disease. Blood Rev. 2007;21:21–36. [PubMed: 16442192]
• Ohneda K, Yamamoto M. Roles of hematopoietic transcription factors GATA-1 and GATA-2 in the development of red blood cell lineage. Acta Haematol. 2002;108:237–45. [PubMed: 12432220]
• Parrella S, Aspesi A, Quarello P, Garelli E, Pavesi E, Carando A, Nardi M, Ellis SR, Ramenghi U, Dianzani I. Loss of GATA-1 full length as a cause of Diamond-Blackfan anemia phenotype. Pediatr Blood Cancer. 2014;61:1319–21. [PMC free article: PMC4684094] [PubMed: 24453067]
• Phillips JD, Steensma DP, Pulsipher MA, Spangrude GJ, Kushner JP. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood. 2007;109:2618–21. [PMC free article: PMC1852202] [PubMed: 17148589]
• Phillips JD, Steensma DP, Spangrude GJ, Kushner JP. Congenital erythropoietic porphyria, beta-thalassemia intermedia and thrombocytopenia due to a GATA1 mutation. Blood. 2005;106:515A.
• Raskind WH, Niakan KK, Wolff J, Matsushita M, Vaughan T, Stamatoyannopoulos G, Watanabe C, Rios J, Ochs HD. Mapping of a syndrome of X-linked thrombocytopenia with Thalassemia to band Xp11-12: further evidence of genetic heterogeneity of X-linked thrombocytopenia. Blood. 2000;95:2262–8. [PubMed: 10733494]
• Roberts I, Alford K, Hall G, Juban G, Richmond H, Norton A, Vallance G, Perkins K, Marchi E, McGowan S, Roy A, Cowan G, Anthony M, Gupta A, Ho J, Uthaya S, Curley A, Rasiah SV, Watts T, Nicholl R, Bedford-Russell A, Blumberg R, Thomas A, Gibson B, Halsey C, Lee PW, Godambe S, Sweeney C, Bhatnagar N, Goriely A, Campbell P, Vyas P. GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood. 2013;122:3908–17. [PMC free article: PMC3995281] [PubMed: 24021668]
• Roy A, Roberts I, Norton A, Vyas P. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. British Journal of Haematology. 2009;147:3–12. [PubMed: 19594743]
• Sankaran VG, Ghazvinian R, Do R, Thiru P, Vergilio JA, Beggs AH, Sieff CA, Orkin SH, Nathan DG, Lander ES, Gazda HT. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012;122:2439–43. [PMC free article: PMC3386831] [PubMed: 22706301]
• Singleton BK, Roxby DJ, Stirling JW, Spring FA, Wilson C, Poole J, Anstee DJ. A novel GATA1 mutation (Stop414Arg) in a family with the rare X-linked blood group Lu(a-b-) phenotype and mild macrothrombocytic thrombocytopenia. Br J Haematol. 2013;161:139–42. [PubMed: 23278136]
• Solis C, Aizencang GI, Astrin KH, Bishop DF, Desnick RJ. Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria. J Clin Invest. 2001;107:753–62. [PMC free article: PMC208941] [PubMed: 11254675]
• Thompson AR, Wood WG, Stamatoyannopoulos G. X-linked syndrome of platelet dysfunction, thrombocytopenia, and imbalanced globin chain synthesis with hemolysis. Blood. 1977;50:303–16. [PubMed: 871527]
• Toki T, Kanezaki R, Kobayashi E, Kaneko H, Suzuki M, Wang R, Terui K, Kanegane H, Maeda M, Endo M, Mizuochi T, Adachi S, Hayashi Y, Yamamoto M, Shimizu R, Ito E. Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome. Blood. 2013;121:3181–4. [PubMed: 23440243]
• Tournamille C, Colin Y, Cartron JP, Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet. 1995;10:224–8. [PubMed: 7663520]
• Tsang AP, Visvader JE, Turner CA, Fujiwara Y, Yu C, Weiss MJ, Crossley M, Orkin SH. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell. 1997;90:109–19. [PubMed: 9230307]
• Tubman VN, Levine JE, Campagna DR, Fleming MD, Neufeld EJ. X-linked gray platelet syndrome due to a GATA1 Arg261Gln mutation. Blood. 2007;109:3297–9. [PubMed: 17209061]
• Waltzer L, Ferjoux G, Bataille L, Haenlin M. Cooperation between the GATA and RUNX factors Serpent and Lozenge during Drosophila hematopoiesis. EMBO J. 2003;22:6516–25. [PMC free article: PMC291817] [PubMed: 14657024]
• Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148–52. [PubMed: 12172547]
• White JG. Platelet pathology in carriers of the X-linked GATA-1 macrothrombocytopenia. Platelets. 2007;18:620–7. [PubMed: 18041654]
• White JG, Nichols WL, Steensma DP. Platelet pathology in sex-linked GATA-1 dyserythropoietic macrothrombocytopenia II. Cytochemistry. Platelets. 2007;18:436–50. [PubMed: 17763153]
• Yu C, Niakan KK, Matsushita M, Stamatoyannopoulos G, Orkin SH, Raskind WH. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood. 2002;100:2040–5. [PMC free article: PMC2808424] [PubMed: 12200364]
• Zucker J, Temm C, Czader M, Nalepa G. A Child With Dyserythropoietic Anemia and Megakaryocyte Dysplasia Due to a Novel 5'UTR GATA1s Splice Mutation. Pediatr Blood Cancer. 2016;63:917–21. [PMC free article: PMC5138049] [PubMed: 26713410]

Author History

Stella T Chou, MD (2006-present)
Melissa A Kacena, PhD (2006-present)
Jessica Kirk, BS; Yale University School of Medicine (2006-2011)
Wendy H Raskind, MD, PhD (2006-present)
Mitchell J Weiss, MD, PhD (2006-present)

Acknowledgments

This work was supported in part by NIH grants NCRR RR025760 and RR025761 (MAK), NIH K08 HL093290 and R01 DK100854 (STC), NIH P30 DK090969 (MJW, STC), P30 DK0724429 (MAK), NIAMS R03 AR055269 (MAK), NIAMS R01 AR060332 (MAK), NIA R01 AG046246 (MAK) and by the American Society of Hematology Scholar Award (STC).

Revision History

• 11 May 2017 (ha) Comprehensive update posted live
• 17 April 2014 (me) Comprehensive update posted live
• 22 March 2011 (me) Comprehensive update posted live
• 30 March 2007 (cd) Revision: prenatal testing clinically available
• 21 February 2007 (cd) Revision: clinical testing available
• 22 November 2006 (me) Review posted live
• 10 August 2006 (whr) Original submission